Serum Angiopoietin-2 and CRP Levels During COPD Exacerbations

References

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed on 15 March 2012).
   Google Scholar
• Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 Aug; 364(9434):613–620.
   PubMed Web of Science ®Google Scholar
• Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6:413–421.
   PubMed Web of Science ®Google Scholar
• Agusti AG, Noguera A, Sauleda J, Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003 Feb; 21(2):347–360.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SFP, Senthilselvan A, Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004 Jul; 59(7):574–580.
   PubMed Web of Science ®Google Scholar
• Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006 Dec; 27(12):552–558.
   PubMed Web of Science ®Google Scholar
• Jackson JR, Seed MP, Kircher CH, The codependence of angiogenesis and chronic inflammation. FASEB J. 1997 May; 11(6):457–465.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 May; 146(5):1029–1039.
   PubMed Web of Science ®Google Scholar
• Zanini A, Chetta A, Imperatori AS, The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res 2010 Sep; 29(11):132.
   Google Scholar
• Walters EH, Soltani A, Reid DW, Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008 Feb; 8(1):39–43.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Kostikas K, Kollia P, Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 2006 Oct; 17(7):128.
   Google Scholar
• Goldie RG, Pedersen KE. Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Clin Exp Pharmacol Physiol 1995 Jun-Jul; 22(6-7): 387–396.
   PubMed Web of Science ®Google Scholar
• Makinde T, Murphy RF, Agrawal DK. Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling. Curr Mol Med 2006 Dec; 6(8):831–841.
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997 Jul; 277(5322):55–60.
   PubMed Web of Science ®Google Scholar
• Suri C, Jones PF, Patan S, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996 Dec; 87(7):1153–1155.
   PubMedGoogle Scholar
• Knox AJ, Stocks J, Sutcliffe A. Angiogenesis and vascular endothelial growth factor in COPD. Thorax 2005 Feb; 60(2):88–89.
   PubMed Web of Science ®Google Scholar
• Gale NW, Thurston G, Hackett SF, Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 2002 Sep; 3(3):411–423.
   Web of Science ®Google Scholar
• Cho YJ, Ma JE, Yun EY, Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 2011 Feb; 16(2):284–290.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Perera WR, Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 Oct; 174(8):867–874.
   PubMed Web of Science ®Google Scholar
• Muller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med 2006 Oct; 174(8):848–849.
   PubMed Web of Science ®Google Scholar
• Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010 Jun; 31(3):267–275.
   PubMed Web of Science ®Google Scholar
• Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 2009 Mar; 15(2):120–125.
   PubMed Web of Science ®Google Scholar
• Ruiz-González A, Lacasta D, Ibarz M, C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. Respirology 2008 Nov; 13(7):1028–1033.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Seemungal TAR, Donaldson GC, Paul EA, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1):1418–1422.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005 Nov; 60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117(5 Suppl 2):398–401.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 Jan; 1(1):27–31.
   PubMed Web of Science ®Google Scholar
• Valipour A, Schreder M, Wolzt M, Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008 Oct; 115(7):225–232.
   PubMed Web of Science ®Google Scholar
• Muller B, Peri G, Doni A, High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002 Oct; 72(4):643–649.
   PubMed Web of Science ®Google Scholar